Abstract 3006: Hyperoxia may be a treatment option for NSCLC
Junko Hamamoto(Keio University), Kenzo Soejima(Keio University), Tetsuo Tani(Keio University), Aoi Kuroda(Keio University), Kota Ishioka(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Tomoko Betsuyaku(Tokyo Medical University), Daisuke Arai(Keio University), Michael G. Edwards(University of Colorado Health), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Masayoshi Miyawaki(Keio University), Hiroyuki Yasuda(Keio University), Makoto Nishino(Keio University)
Cited by 0
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565